Collaboration Deals in Biotechnology 2021-2026

Understand how biotechnology companies use collaboration partnerships to access capabilities, advance innovation and create development and commercialization opportunities.

Collaboration Deals in Biotechnology provides comprehensive intelligence on 1,702 collaboration deals involving biotechnology companies.

The report examines how biotech companies use collaboration agreements to combine technologies, expertise, development capabilities and commercial resources with those of external partners.

These partnerships can play a critical role in advancing emerging technologies and therapeutic assets, accessing capabilities that may not exist internally, sharing development risk and creating routes towards later-stage development and commercialization.

Rather than simply identifying transactions, the report enables users to understand who is collaborating, where partnering activity is concentrated, how agreements are structured, and what can be learned from disclosed financial terms and publicly available contract documents.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, alliance management and legal teams involved in biotechnology partnering.

Understand the biotechnology collaboration landscape

The report analyzes collaboration dealmaking from 2021 to 2026, including:

• Trends in collaboration dealmaking by year
• Stage of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active collaboration dealmakers
• Leading deals by disclosed value
• Strategic reasons for entering collaboration agreements
• How biotechnology collaboration strategies are evolving
• This enables users to see where collaboration activity is concentrated, identify technologies and therapeutic areas attracting partnership activity and understand which companies are most actively engaging with external innovation.
• Understand how collaboration agreements are structured
• Biotechnology collaboration agreements can range from early research partnerships and technology collaborations through to broader development and commercialization alliances.

The report provides intelligence to help users examine areas including:

• Research and development responsibilities
• Rights granted or optioned
• Development funding and cost allocation
• Intellectual property ownership and licensing rights
• Governance and decision-making
• Exclusivity provisions
• Development and regulatory responsibilities
• Manufacturing and supply
• Commercialization rights and responsibilities
• Geographic and market rights
• Financial terms where disclosed
• Term and termination provisions
• This provides useful reference points for companies considering potential collaboration structures or preparing for partnering discussions.
• Benchmark leading deals and disclosed financial terms
• The report identifies leading biotechnology collaboration transactions by disclosed deal value and provides access to available financial information associated with individual agreements.

Users can investigate disclosed elements including:

• Upfront payments
• Development and regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity investments
• Research funding
• Other financial commitments where available
• This enables users to place potential transactions into the context of comparable real-world biotechnology collaborations and establish more informed benchmarks for deal preparation and negotiation.
• Identify leading biotechnology collaboration dealmakers
• The report profiles the Top 25 most active collaboration dealmakers, providing insight into companies that repeatedly use collaboration partnerships to access or develop technologies and assets.

Individual deal histories can help users understand how specific companies approach external innovation and can support:

• Partner identification
• Search and evaluation
• Competitor analysis
• Business development strategy
• Assessment of partnering behaviour
• For biotechnology companies seeking development or commercial partners, this can also help identify organizations with a demonstrated appetite for particular technologies, therapeutic areas or stages of development.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying collaboration contract documents.
• These agreements can reveal substantially more detail than company announcements alone, enabling users to examine how selected partners have addressed areas such as development obligations, intellectual property, exclusivity, governance, financial arrangements, commercialization rights and termination.
• For teams preparing for or negotiating collaboration agreements, these real-world contracts provide valuable insight into how comparable biotechnology partnerships have been documented in practice.
• Comprehensive collaboration deal directory
• The report includes a comprehensive directory of 1,702 biotechnology collaboration deals, allowing users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable collaborations, potential partners and relevant transaction structures when developing partnering strategies.
• Search and Evaluation teams
• Identify companies active in specific technologies, therapeutic areas and development stages and investigate their previous partnering activity.
• Biotechnology Management teams
• Understand how peer companies are using collaboration partnerships to access development capabilities, funding and routes towards commercialization.
• Corporate and R&D Strategy teams
• Track how biotechnology companies are using external partnerships to complement internal technologies, assets and capabilities.
• Alliance Management teams
• Examine how responsibilities, governance and ongoing partner obligations have been structured across comparable collaborations.
• Legal and Transaction teams
• Review deal structures and publicly available contract language to support transaction preparation and negotiation.
• Competitive and Market Intelligence teams
• Analyze collaboration activity by company, therapy area, technology and stage of development to identify important partnering trends.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying biotechnology collaboration intelligence to the customer's own business, technologies, assets or partnering objectives.
• Depending on requirements, this can include relevant comparable deals, prospective partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's partnering situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.